Research programme: peripheral neuropathy therapeutics - WinSanTorAlternative Names: WST B1
Latest Information Update: 10 Aug 2016
At a glance
- Originator WinSanTor
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Neuropathic pain
Most Recent Events
- 10 Aug 2016 Early research in Neuropathic pain in USA (unspecified route)